- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01157078
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kanpur, India
- Research Site
-
Mysore, India
- Research Site
-
-
Andh Prad
-
Visakhapatnam, Andh Prad, India
- Research Site
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India
- Research Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India
- Research Site
-
-
Gujrat
-
Rajkot, Gujrat, India
- Research Site
-
-
Karnataka
-
Mangalore, Karnataka, India
- Research Site
-
-
Mahara
-
Nashik, Mahara, India
- Research Site
-
-
Maharashtra
-
Aurangabad, Maharashtra, India
- Research Site
-
Pune, Maharashtra, India
- Research Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India
- Research Site
-
Khatipura, Rajasthan, India
- Research Site
-
-
Tamilnadu
-
Madurai, Tamilnadu, India
- Research Site
-
-
Uttar Prad
-
Varanasi, Uttar Prad, India
- Research Site
-
-
-
-
Alabama
-
Tuscaloosa, Alabama, United States
- Research Site
-
-
Arizona
-
Tucson, Arizona, United States
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Research Site
-
-
California
-
Chino, California, United States
- Research Site
-
Costa Mesa, California, United States
- Research Site
-
Encino, California, United States
- Research Site
-
Escondido, California, United States
- Research Site
-
Los Alamitos, California, United States
- Research Site
-
Oceanside, California, United States
- Research Site
-
Pico Rivera, California, United States
- Research Site
-
San Diego, California, United States
- Research Site
-
Torrance, California, United States
- Research Site
-
-
Connecticut
-
Hamden, Connecticut, United States
- Research Site
-
-
Florida
-
Coral Springs, Florida, United States
- Research Site
-
Jacksonville, Florida, United States
- Research Site
-
Orange City, Florida, United States
- Research Site
-
Orlando, Florida, United States
- Research Site
-
Tampa, Florida, United States
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States
- Research Site
-
-
Kansas
-
Prairie Village, Kansas, United States
- Research Site
-
-
Kentucky
-
Florence, Kentucky, United States
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, United States
- Research Site
-
-
Missouri
-
St. Louis, Missouri, United States
- Research Site
-
-
New York
-
New York, New York, United States
- Research Site
-
Rochester, New York, United States
- Research Site
-
Staten Island, New York, United States
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Research Site
-
Dayton, Ohio, United States
- Research Site
-
Middleburg Heights, Ohio, United States
- Research Site
-
-
Oregon
-
Portland, Oregon, United States
- Research Site
-
Salem, Oregon, United States
- Research Site
-
-
Pennsylvania
-
Norristown, Pennsylvania, United States
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States
- Research Site
-
-
Texas
-
Dallas, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
-
Vermont
-
Woodstock, Vermont, United States
- Research Site
-
-
Washington
-
Seattle, Washington, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent before initiation of any study-related procedures.
- The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.
- Out-patient status at enrollment and randomization.
Exclusion Criteria:
- Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.
- Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide.
- History of renal insufficiency or impairment or conditions that could affect absorption or metabolism of the investigational product in this patient population
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TC-5214
Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
|
Tablet, oral, twice daily for 8 weeks
|
PLACEBO_COMPARATOR: Placebo
Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
|
Tablet, oral, twice daily for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score at end of treatment (Week 16) was calculated. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Randomization (Week 8) to end of treatment (Week 16)
|
Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
Time Frame: Week 16
|
The percentage of patients with a MADRS total score of ≤8 at end of treatment (Week 16) was calculated. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Week 16
|
Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16); Week 10, Week 12, Week 14, and Week 16
|
The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score and a MADRS total score of ≤12 at Week 10, Week 12, Week 14, and end of treatment (Week 16) was calculated. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Randomization (Week 8) to end of treatment (Week 16); Week 10, Week 12, Week 14, and Week 16
|
Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16); Week 12, Week 14, and Week 16
|
The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score and a MADRS total score of ≤12 at Week 12, Week 14, and end of treatment (Week 16) was calculated. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Randomization (Week 8) to end of treatment (Week 16); Week 12, Week 14, and Week 16
|
Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)
Time Frame: Week 12, Week 14, Week 16
|
The percentage of patients with a MADRS total score of ≤8 at Week 12, Week 14, and end of treatment (Week 16)was calculated. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Week 12, Week 14, Week 16
|
Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 17-item, clinician-rated scale that assesses depressive symptoms.
The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent.
The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52.
Higher HAMD-17 scores indicate more severe depression.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline).
Each item is scored on a 1 to 7 scale.
Higher CGI-S scores indicate greater illness severity.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of "Very Much Improved" or "Much Improved" From Randomization (Week 8) to End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline).
Each item is scored on a 1 to 7 scale.
CGI-I scores >4 indicate worsening, while scores <4 indicate improvement.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in MADRS Total Score From Randomization (Week 8) to Week 10
Time Frame: Randomization (Week 8) to Week 10
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Randomization (Week 8) to Week 10
|
Change in MADRS Total Score From Randomization (Week 8) to Week 12
Time Frame: Randomization (Week 8) to Week 12
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Randomization (Week 8) to Week 12
|
Change in MADRS Total Score From Randomization (Week 8) to Week 14
Time Frame: Randomization (Week 8) to Week 14
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Randomization (Week 8) to Week 14
|
Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
Sheehan Disability Scale (SDS) is 5-item, self-administered scale that measures the extent a patient is impaired by their disease.
Higher scores indicate more severe impairment.
The SDS total score is calculated as the sum of the score for the 3 inter-correlated domains (school/work, social life, and family life/home responsibilities) and ranges from 0 (unimpaired) to 30 (highly impaired).
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 5-item, self-administered scale that measures the extent a patient is impaired by their disease.
Higher scores indicate more severe impairment.
The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities.
The numerical rating for the work/school domain score is 0- 10, where 10 is considered to be 'highly impaired'.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 5-item, self-administered scale that measures the extent a patient is impaired by their disease.
Higher scores indicate more severe impairment.
The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities.
The numerical rating for the SDS social life domain score is 0- 10, where 10 is considered to be 'highly impaired'.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A 5-item, self-administered scale that measures the extent a patient is impaired by their disease.
Higher scores indicate more severe impairment.
The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities.
The numerical rating for the SDS family life/home responsibilities domain score is 0- 10, where 10 is considered to be 'highly impaired'.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
The Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form)total score is derived by summing item scores 1 to 14. Higher scores are indicative of greater enjoyment or satisfaction in each domain.
The Q-LES-Q-SF % maximum total score is calculated as 100% × (Q-LES-Q-SF total score - 14) / 56, and can range from 0% to 100%.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A self-assessment questionnaire that provides 2 measures of health status.
The EQ-5D index score is a weighted linear combination over 5 dimensions of health status.
The score for each of the 5 dimensions can range from 1 to 3, and an equation is used to calculate the EQ-5D index score.
The EQ-5D index score can range from possible negative values (minimum -0.415) to a maximum of 1.0.
The EQ-VAS is a visual analog scale with a range of 0 to 100.
For both variables, a higher score indicates a better health state.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Change in MADRS Total Score From Randomization (Week 8) to Week 9
Time Frame: Randomization (Week 8) to Week 9
|
A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. MADRS is 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms. |
Randomization (Week 8) to Week 9
|
Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
The Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) measures the patient's satisfaction with medication and overall quality of life. The 15th item queries respondents' satisfaction with the medication they are taking, rated on a 1 to 4 scale, score 0 indicates that no medication was taken. Higher scores are indicative of greater satisfaction. |
Randomization (Week 8) to end of treatment (Week 16)
|
Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
The Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) measures the patient's satisfaction with medication and overall quality of life. The 16th item is a global rating of overall life satisfaction and contentment, rated on a 1 to 5 scale. Higher scores are indicative of greater satisfaction. |
Randomization (Week 8) to end of treatment (Week 16)
|
Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)
Time Frame: Randomization (Week 8) to end of treatment (Week 16)
|
A self-administered scale to be used by clinical subjects to rate suffering over the past week with regard to irritability symptoms.
The total SIS score is the sum of 7 items, and ranges from 0 to 70.
Each item is assessed on an 11-point scale where 0=not at all, 1-3=mildly, 4-6=moderately, 7-9=markedly, and 10=extremely.
The SIS also records the number of days impaired by irritability.
|
Randomization (Week 8) to end of treatment (Week 16)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Hans A. Eriksson, MD, Ph.D, MBA, AstraZeneca R&D
- Principal Investigator: Bernadette D'Souza, MD, Midwest Clinical Research Center, Ohio
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D4130C00002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on TC-5214
-
Targacept Inc.TerminatedRefractory HypertensionUnited States
-
AstraZenecaCompletedElderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.Sweden
-
AstraZenecaCompleted
-
Targacept Inc.CompletedOveractive BladderUnited States
-
Atacama TherapeuticsCompletedPalmar HyperhidrosisUnited States
-
AstraZenecaCompletedRenal Impairment | Healthy Volunteers | Pharmacokinetics | PatientsUnited States
-
AstraZenecaCompletedHealthy SubjectsUnited States
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
AstraZenecaTargacept Inc.CompletedDepression | Major Depressive DisorderUnited States, India, Puerto Rico